Texas bus biz plans to get on the road again

BACK ON TRACK

After a weeks-long, COVID-caused intermission, Texas-based Vonlane is hitting highways with daily routes starting July 1. Photo courtesy of Vonlane

Vonlane buses are revving their engines again. After weeks without service due to the coronavirus pandemic, the Dallas-based luxury bus operator will restart all routes serving Texas on July 1.

In a June 9 message to customers, Vonlane said daily departures resuming July 1 would include:

  • Houston-Dallas
  • Houston-Fort Worth
  • Houston-Austin
  • Houston-San Antonio
  • Dallas-Austin
  • Dallas-Oklahoma City
  • Fort Worth-Austin

Coming soon are routes to Nashville and Atlanta, with details to be announced, the company says.

As the coronavirus started to cripple travel in March, Vonlane temporarily eliminated four routes serving Texas. "While we are significantly impacted by the circumstances of the day," Vonlane founder and CEO Alex Danza said then. "Our goal is to be a solution for your urgent personal travel."

But by April 15, when most of Texas was sheltering in place, Vonlane suspended operations due to lack of demand. Limited routes between Dallas, Austin, and Houston resumed May 29.

Like many businesses, Vonlane also pivoted its operation in new directions during the shutdown.

On Memorial Day, the company announced it was expanding its services to include out-of-state charters. It now offers bespoke charter service to popular destinations across the continental U.S. like Colorado, Florida, and New Orleans, as an alternative to flying.

Passengers who book a private charter have access to up to 22 seats, can leave from a specific departure point of their choice, and travel to any destination, the company says.

Vonlane also rolled out a parcel shipping service in Texas. "Need to get something to a loved one, friend, or business associate in Austin, Dallas, or Houston today?" Danza said in the announcement. "Send it aboard the next Vonlane departure for a flat fee." More details on the service are outlined here.

In putting its luxury buses back on the road, Vonlane is adopting a number of measures designed to curb the spread of the coronavirus, such as limiting the passenger count to 13 by blocking all aisle seats through June 30; requiring passengers and employees to wear face coverings; and checking passengers' temperatures before boarding.

"As one of our core values, the safety of our passengers, crew, and fellow over-the-road travelers is our top priority," Danza said in a May 26 release announcing the charters. "In light of the current coronavirus situation, Vonlane is maximizing our efforts to make sure the Vonlane experience is as responsible, safe, and comfortable as our passengers have come to expect."

Vonlane launched its high-end bus service in 2014 with the Dallas-to-Austin route. Each bus, which holds fewer than two dozen passengers, features amenities like WiFi, satellite TV and radio, and leather seats.

Reservations can be booked online, and may be canceled and fully refunded up to 24 hours before departure.

---

This article originally ran on CultureMap.

Vonlane is now driving beyond Texas. Courtesy photo

Texas travel company revs up for out-of-state expansion

ON THE ROAD AGAIN

In response to pandemic-triggered travel interruptions, Dallas-based high-end bus operator Vonlane is expanding its services to include out-of-state charters and in-state parcel shipping.

In a Memorial Day message to customers, Vonlane founder and CEO Alex Danza said the company now offers charter service to destinations across the continental U.S., citing examples like Colorado, Florida, and New Orleans. Danza says this provides long-distance travel when airline flights aren't an option.

"These bespoke trips allow you to travel privately with your friends, family, and business associates aboard your own Private Jet on Wheels," Danza wrote. "You name the pickup location, destination, and dates while we handle all of the logistics."

Vonlane has also rolled out a same-day parcel shipping service in Texas, where packages basically hitch a ride with the motor coaches.

"Need to get something to a loved one, friend, or business associate in Austin, Dallas, or Houston today?" Danza said. "Send it aboard the next Vonlane departure for a flat fee."

Amid the coronavirus pandemic, Vonlane halted its city-to-city bus service due to a lack of demand. Some routes returned on May 29, including Dallas-Austin, Dallas-Houston, and Houston-Austin.

In putting its luxury buses back on the road, Vonlane is adopting a number of measures designed to curb the spread of the coronavirus, such as limiting the passenger count to 13 by blocking all aisle seats through June 30; requiring passengers and employees to wear face coverings; and checking passengers' temperatures before boarding.

"As one of our core values, the safety of our passengers, crew, and fellow over-the-road travelers is our top priority," Danza says in a May 26 release. "In light of the current coronavirus situation, Vonlane is maximizing our efforts to make sure the Vonlane experience is as responsible, safe, and comfortable as our passengers have come to expect."

Danza says Vonlane hopes to resurrect its Fort Worth, San Antonio, and Oklahoma City routes "as soon as feasible."

------

This article originally ran on CultureMap.

Some seats have been blocked to enable social distancing. Courtesy of Vonlane

Texas business-focused bus service curbs routes in response to COVID-19

bus stops

As the coronavirus cripples travel, Dallas-based luxury bus operator Vonlane LLC has temporarily eliminated four routes serving Texas.

In a March 24 email to customers, Vonlane founder and CEO Alex Danza said the four routes that have been paused are:

  • Houston-San Antonio
  • Dallas-Oklahoma City
  • Fort Worth-Austin
  • Fort Worth-Houston

As a result of these changes, no service is currently available to or from Fort Worth.

"While we are significantly impacted by the circumstances of the day," Danza wrote, "we continue to operate a minimal schedule between Austin, Dallas, and Houston as an essential public transportation provider. Our goal is to be a solution for your urgent personal travel."

Once the coronavirus pandemic has subsided, Vonlane will return to its normal schedule of 70 to 78 daily departures in Texas and Oklahoma, according to the email.

For those passengers who travel on Vonlane buses, some seats have been blocked to enable six feet of social distance, Danza wrote. Other coronavirus safety measures include disinfecting bus interiors, stocking buses with hand sanitizer, and outfitting on-board attendants with gloves to wear while serving food and beverages.

"Everyone at Vonlane is excited about the day we see you all aboard the coaches someday soon," Danza wrote.

Vonlane launched its high-end bus service in 2014 with the Dallas-to-Austin route. Each bus, which holds fewer than two dozen passengers, features amenities like WiFi, satellite TV and radio, and leather seats.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

3 Houston startups named most innovative in Texas by LexisNexis

report card

Three Houston companies claimed spots on LexisNexis's 10 Most Innovative Startups in Texas report, with two working in the geothermal energy space.

Sage Geosystems claimed the No. 3 spot on the list, and Fervo Energy followed closely behind at No. 5. Fintech unicorn HighRadius rounded out the list of Houston companies at No. 8.

LexisNexis Intellectual Property Solutions compiled the report. It was based on each company's Patent Asset Index, a proprietary metric from LexisNexis that identifies the strength and value of each company’s patent assets based on factors such as patent quality, geographic scope and size of the portfolio.

Houston tied with Austin, each with three companies represented on the list. Caris Life Sciences, a biotechnology company based in Dallas, claimed the top spot with a Patent Asset Index more than 5 times that of its next competitor, Apptronik, an Austin-based AI-powered humanoid robotics company.

“Texas has always been fertile ground for bold entrepreneurs, and these innovative startups carry that tradition forward with strong businesses based on outstanding patent assets,” Marco Richter, senior director of IP analytics and strategy for LexisNexis Intellectual Property Solutions, said in a release. “These companies have proven their innovation by creating the most valuable patent portfolios in a state that’s known for game-changing inventions and cutting-edge technologies.We are pleased to recognize Texas’ most innovative startups for turning their ideas into patented innovations and look forward to watching them scale, disrupt, and thrive on the foundation they’ve laid today.”

This year's list reflects a range in location and industry. Here's the full list of LexisNexis' 10 Most Innovative Startups in Texas, ranked by patent portfolios.

  1. Caris (Dallas)
  2. Apptronik (Austin)
  3. Sage Geosystems (Houston)
  4. HiddenLayer (Austin)
  5. Fervo Energy (Houston)
  6. Plus One Robotics (San Antonio)
  7. Diligent Robotics (Austin)
  8. HighRadius (Houston)
  9. LTK (Dallas)
  10. Eagle Eye Networks (Austin)

Sage Geosystems has partnered on major geothermal projects with the United States Department of Defense's Defense Innovation Unit, the U.S. Air Force and Meta Platforms. Sage's 3-megawatt commercial EarthStore geothermal energy storage facility in Christine, Texas, was expected to be completed by the end of last year.

Fervo Energy fully contracted its flagship 500 MW geothermal development, Cape Station, this spring. Cape Station is currently one of the world’s largest enhanced geothermal systems (EGS) developments, and the station will begin to deliver electricity to the grid in 2026. The company was recently named North American Company of the Year by research and consulting firm Cleantech Group and came in at No. 6 on Time magazine and Statista’s list of America’s Top GreenTech Companies of 2025. It's now considered a unicorn, meaning its valuation as a private company has surpassed $1 billion.

Meanwhile, HighRadius announced earlier this year that it plans to release a fully autonomous finance platform for the "office of the CFO" by 2027. The company reached unicorn status in 2020.

---

This article originally appeared on Energy Capital HTX.

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.


View All Listings